October 12, 2015November 5, 2015

MediciNova’s MN-001 (Tipelukast) IPF Therapy Progresses to Phase 2 Clinical Trial

MediciNova, Inc. announced the progression of MN-001 (tipelukast), a small molecule drug to treat idiopathic pulmonary fibrosis (IPF), into phase II clinical trials. This development follows the culmination of the ... Read more

February 16, 2015February 18, 2015

MediciNova Announces FDA Clearance for Phase 2 Trial Of MN-001 In IPF

News

MediciNova, Inc., a biopharmaceutical company, recently announced that the FDA (U.S. Food and Drug Administration) has approved thecompany’s protocol for a MN-001 (tipelukast) clinical trial to address moderate to severe idiopathic pulmonary fibrosis (IPF). Supported ... Read more